Sogroya

Chemical Namesomapacitan-beco
Dosage FormInjection (subcutaneous; 10 mg/1.5 mL, 6.7 mg/mL)
Drug ClassHormones
SystemEndocrine
CompanyNovo Nordisk Inc.
Approval Year2020

Indication

  • For replacement of growth hormone in adults with growth hormone deficiency (GHD).
Last updated on 12/9/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Sogroya (somapacitan-beco) Prescribing Information. 2020Novo Nordisk Inc., Plainsboro, NJ